ERIC 2022 | The importance of real-world data in CLL & efficacy of BTK and Bcl-2 inhibitors in the real world
Antonio Cuneo, MD, St. Anna University Hospital, Ferrara, Italy, explains the importance of real-world data (RWD) in chronic lymphocytic leukemia (CLL), commenting on the issue of selection bias in clinical trials. Dr Cuneo explains that real-world studies evaluating the safety and efficacy of BTK and Bcl-2 inhibitors in CLL patients demonstrated similar results to those reported in clinical trials, although there was a higher BTK inhibitor discontinuation rate probably due to a higher comorbidity burden in the real-world CLL population. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
